Scworx Corp. is a US-listed company in the health care technology industry. Its financial year ends in December.
Loading chart…
Third-party market data · may be delayed
Under review: every model's value for Scworx Corp. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.
Under review: cash-flow, stock-pay or share-count figures missing or out of date. We'll show the comparison once resolved.
Scworx Corp. valuation: adjust assumptions and compare models →
Scworx has little or no product revenue yet. The diluted share count is up 95.4% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades C+. It passes 2 of our 3 financial-health checks.
Our model value for Scworx is under review, so past values are not shown until it is resolved.
Source: 10-Q filed August 14, 2026 on SEC EDGAR · Financials · Valuation
Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.
Where it stands out: long-term debt as % of assets of 0.0% ranks 1 of 15 health care technology companies we cover. Where it lags: change in share count of 207.2% ranks 18 of 19 health care technology companies we cover.
Current signal Gross margin expanding: TTM gross margin reached 44.7%, up 23.2pp year over year.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Loading chart…
Third-party market data · may be delayed
Company announcements, filed results and changes that matter to shareholders.
The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.
We value Scworx Corp. as an operating company, with every model that fits that kind of business. Cost of equity 9.4%: the 10-year Treasury yield (4.9%) plus a beta of 0.99 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | ~$23 ~$21–$140 | Left out: out of range vs price (16.88x) |
| Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. | — | Combined value withheld. Review the individual models and their assumptions. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Scworx Corp. with Health Care Technology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
| At fiscal year end | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Share price | $186732.00 | $59508.00 | $8310.60 | $7749.00 | $3645.00 | $3483.00 | $1069.20 | $331.20 | $304.20 | $33.30 |
| Market value | $687.3bn | $211.8bn | $12.4bn | $16.2bn | $11.0bn | $12.2bn | $4.3bn | $1.7bn | $2.2bn | $242m |
| + Net debt (− = net cash) | −$5m | $284841 | $960858 | −$487953 | −$376425 | −$71075 | −$249462 | −$91436 | −$86994 | −$2m |
| Enterprise value | $687.3bn | $211.8bn | $12.4bn | $16.2bn | $11.0bn | $12.2bn | $4.3bn | $1.7bn | $2.2bn | $241m |
| Multiples | ||||||||||
| Price / sales | n/m | n/m | n/m | n/m | n/m | n/m | n/m | n/m | n/m | 84.2x |
| Price / earnings | — | — | — | — | — | — | — | — | — | — |
| Price / free cash flow | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
Weak moat
How hard Scworx's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
Net income has been a median -46.5% of total assets over 10 years.
Gross margin has been a median 35.0%, moving by 22.9 percentage points (standard deviation) across 5 years.
Operating margin has been a median -76.9%; its worst year was -340.8%.
The diluted share count fell 99.6% over five years; stock-based pay has been a median 43.2% of revenue.
AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (31 before it).
No analyst estimates are published for Scworx Corp.: too few analysts cover it.
Last 3 years −99.6%
| Part | Then | Now | Effect |
|---|---|---|---|
| Revenue (last 12 months) | $4m | $3m | −26.9% |
| P/S multiple | 6.1x | 0.0x | −99.5% |
| Share count | 0m | 0m | +3.6% |
Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| WORX | −4% | −69% | −69% | −8% | −89% | −96% |
| Industry peers (median) | −14% | −60% | −16% | −24% | −27% | −26% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| WORX | 33% | 25% | 42% | 33% | 8% | 27% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| WORX | −69% | −73% | −83% | −77% | −91% | −98% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since October 6, 2016: 100% from October 7, 2016 to October 16, 2026. Getting back needed a 17285770% gain, and the shares have not yet recovered.
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Revenue (TTM) |
|---|---|
| FY23 Q3 | $3.9M |
| FY23 Q4 | $3.8M |
| FY24 Q1 | $3.6M |
| FY24 Q2 | $3.4M |
| FY24 Q3 | $3.2M |
| FY24 Q4 | $3M |
| FY25 Q1 | $2.9M |
| FY25 Q2 | $2.8M |
| FY25 Q3 | $2.8M |
| FY25 Q4 | $2.9M |
| FY26 Q1 | $2.9M |
| FY26 Q2 | $2.9M |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Revenue growth, TTM YoY |
|---|---|
| FY23 Q3 | -7.9% |
| FY23 Q4 | -5.8% |
| FY24 Q1 | -9.6% |
| FY24 Q2 | -15.8% |
| FY24 Q3 | -17.8% |
| FY24 Q4 | -21.4% |
| FY25 Q1 | -19.9% |
| FY25 Q2 | -15.8% |
| FY25 Q3 | -13.6% |
| FY25 Q4 | -3.7% |
| FY26 Q1 | 0.2% |
| FY26 Q2 | 3.1% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Operating margin (TTM) |
|---|---|
| FY23 Q3 | -42.3% |
| FY23 Q4 | -38.1% |
| FY24 Q1 | -34.0% |
| FY24 Q2 | -41.2% |
| FY24 Q3 | -28.7% |
| FY24 Q4 | -42.1% |
| FY25 Q1 | -48.8% |
| FY25 Q2 | -49.4% |
| FY25 Q3 | -41.2% |
| FY25 Q4 | -33.3% |
| FY26 Q1 | -26.2% |
| FY26 Q2 | -20.1% |
| Fiscal year | 2016 Dec 2016 | 2017 Dec 2017 | 2018 Dec 2018 | 2019 Dec 2019 | 2020 Dec 2020 | 2021 Dec 2021 | 2022 Dec 2022 | 2023 Dec 2023 | 2024 Dec 2024 | 2025 Dec 2025 | LTM Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income | |||||||||||
| Revenue | 1 | 0 | 3 | 6 | 5 | 5 | 4 | 4 | 3 | 3 | 3 |
| Gross profit | 0 | 2 | 1 | 1 | — | — | 1 | 1 | 1 | 1 | 1 |
| EBITDA | −5 | −3 | −0 | −12 | −6 | −4 | — | — | — | −1 | — |
| Operating income | −5 | −3 | −0 | −12 | −6 | −4 | −2 | −1 | −1 | −1 | −1 |
| Net income | −4 | −12 | −0 | −11 | −7 | −4 | −2 | −4 | −1 | −4 | −2 |
| Diluted EPS | −$0.07 | −$3.36 | −$0.02 | −$0.36 | −$0.16 | −$0.07 | −$0.46 | −$0.77 | −$0.16 | −$0.61 | — |
| Growth (year on year) | |||||||||||
| Revenue | — | −62.7% | +>999% | +62.1% | −6.0% | −11.1% | −12.8% | −5.8% | −21.4% | −3.7% | +3.1% |
| Margins | |||||||||||
| Gross margin | 35.0% | — | 14.8% | 21.0% | — | — | 35.0% | 33.4% | 25.0% | 32.0% | 44.7% |
| EBITDA margin | −828.3% | <−999% | −4.4% | −214.3% | −115.4% | −80.7% | — | — | — | −33.3% | — |
| Operating margin | −830.5% | <−999% | −4.4% | −214.4% | −116.0% | −82.3% | −52.6% | −38.1% | −42.1% | −33.3% | −20.1% |
| Net margin | −703.3% | <−999% | −11.1% | −203.9% | −142.0% | −82.3% | −45.7% | −104.6% | −38.0% | −154.4% | −80.5% |
| Free-cash-flow margin | — | — | — | −86.6% | — | — | — | — | — | −54.0% | −25.5% |
| Cash flow | |||||||||||
| Cash from operations | −2 | −6 | −0 | −5 | −1 | −1 | −1 | −1 | −1 | −2 | −1 |
| Capital spending | — | — | — | 0 | — | — | — | — | — | 0 | 0 |
| Free cash flow | — | — | — | −5 | — | — | — | — | — | −2 | −1 |
| Stock-based pay | 3 | 1 | 1 | 7 | 3 | 3 | 1 | 0 | — | 0 | — |
| Free cash flow after stock pay | — | — | — | −12 | — | — | — | — | — | −2 | — |
| Balance sheet | |||||||||||
| Cash | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 |
| Total debt | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Net debt (negative = net cash) | −5 | 0 | 1 | −0 | −0 | −0 | −0 | −0 | −0 | −2 | −1 |
| Diluted shares | 4m | 4m | 1m | 2m | 3m | 4m | 4m | 5m | 7m | 7m | — |
| Quarter | 2024 Q3 Sept 2024 | 2024 Q4 Dec 2024 | 2025 Q1 Mar 2025 | 2025 Q2 Jun 2025 | 2025 Q3 Sept 2025 | 2025 Q4 Dec 2025 | 2026 Q1 Mar 2026 | 2026 Q2 Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| Revenue | 760 | 676 | 720 | 683 | 706 | 769 | 745 | 706 |
| Gross profit | 133 | 158 | 137 | 180 | 252 | 350 | 374 | 330 |
| EBITDA | — | — | — | — | — | — | −135 | −120 |
| Operating income | −393 | −380 | −334 | −294 | −139 | −192 | −136 | −121 |
| Net income | −425 | −195 | −476 | −1,906 | −1,313 | −749 | −174 | −121 |
| Diluted EPS | −$0.14 | −$0.04 | −$1.85 | −$41.13 | −$27.00 | $0.15 | −$1.92 | −$1.35 |
| Growth (year on year) | ||||||||
| Revenue | −16.2% | −25.8% | −11.3% | −8.0% | −7.1% | +13.8% | +3.4% | +3.4% |
| Margins | ||||||||
| Gross margin | 17.5% | 23.4% | 19.0% | 26.4% | 35.7% | 45.6% | 50.2% | 46.8% |
| EBITDA margin | — | — | — | — | — | — | −18.1% | −17.0% |
| Operating margin | −51.8% | −56.3% | −46.4% | −43.0% | −19.7% | −25.0% | −18.2% | −17.1% |
| Net margin | −55.9% | −28.9% | −66.1% | −279.2% | −186.0% | −97.4% | −23.3% | −17.1% |
| Free-cash-flow margin | −80.2% | −19.9% | −56.2% | −95.5% | −50.7% | −16.8% | −33.9% | −0.8% |
| Cash flow | ||||||||
| Cash from operations | −610 | −134 | −405 | −652 | −358 | −129 | −253 | −6 |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −610 | −134 | −405 | −652 | −358 | −129 | −253 | −6 |
| Stock-based pay | — | — | — | — | — | — | 12 | 4 |
| Free cash flow after stock pay | — | — | — | — | — | — | −265 | −9 |
| Last 12 months unless stated | WORX | AIFF | ONMD | MNDR | DRIO | HCTI | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $3m | $2m | $1m | $8m | $21m | $26m | $292m |
| Revenue growth, last 12 months | 3.1% | 320.3% | 216.5% | 1.2% | −22.6% | 116.4% | 8.8% |
| Revenue growth, 3-year average | −9.9% | −41.3% | — | — | −7.6% | −14.9% | 0.8% |
| Revenue growth, latest quarter | 3.4% | 71.9% | 88.4% | — | −3.6% | 158.4% | 7.4% |
| Gross margin | 44.7% | 44.6% | −68.8% | 21.2% | 58.2% | 21.5% | 58.6% |
| Operating margin | −20.1% | −508.1% | −695.7% | — | −151.6% | −57.4% | −12.5% |
| Operating margin, 3-year average | −36.9% | <−999% | <−999% | — | −213.6% | −40.6% | −18.8% |
| Net margin | −80.5% | −506.2% | −584.2% | −41.2% | −169.9% | −66.3% | −12.5% |
| Cash from operations / revenue | −25.5% | −388.6% | −472.3% | −19.7% | −120.7% | −62.4% | 9.7% |
| Free-cash-flow margin | −86.6% | −388.6% | −473.4% | −19.7% | −121.3% | −62.4% | 9.2% |
| Free-cash-flow margin, 3-year average | — | <−999% | −910.1% | — | −144.7% | −44.7% | 8.2% |
| Stock pay / revenue | 9.5% | 62.0% | 173.1% | 19.9% | 33.6% | 3.2% | 9.5% |
| Change in share count | 207.2% | 27.7% | 62.6% | 265.5% | 25.9% | — | 2.9% |
| Measure | Company | Peer median | Rank |
|---|---|---|---|
| Revenue growth Growth | 3.1% | 8.8% | 14 of 23 |
| Change in growth rate Growth | +2.9pp | -0.3pp | 6 of 23 |
| Gross margin Profitability | 44.7% | 58.2% | 10 of 14 |
| Operating margin Profitability | -20.1% | -6.6% | 13 of 22 |
| Net margin Profitability | -80.5% | -12.5% | 18 of 23 |
| Long-term debt as % of assets Balance sheet | 0.0% | 20.1% | 1 of 15 |
| Change in share count Balance sheet | 207.2% | 2.6% | 18 of 19 |
| Days sales outstanding Balance sheet | 33 days | 58 days | 2 of 21 |
Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| Financial statements | SEC 10-K and 10-Q filings | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
New research on the companies we cover arrives in the weekly email. Free, one email a week.
